The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Dec. 10, 2024
Filed:
Apr. 25, 2019
Applicants:
Biogen MA Inc., Cambridge, MA (US);
Neurimmune Ag, Schlieren, CH;
Inventors:
Jan Grimm, Dübendorf, CH;
Fabio Montrasio, Schindellegi, CH;
Isin Dalkilic-Liddle, Watertown, MA (US);
Mia Marie Rushe, Everett, MA (US);
Joseph Walter Arndt, Swampscott, MA (US);
Assignees:
Neurimmune AG, Schlieren, CH;
Biogen MA Inc., Cambridge, MA (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); A61K 47/68 (2017.01); A61K 49/00 (2006.01); A61K 51/10 (2006.01); C07K 16/44 (2006.01); G01N 33/53 (2006.01);
U.S. Cl.
CPC ...
C07K 16/44 (2013.01); A61K 47/6835 (2017.08); A61K 49/0002 (2013.01); A61K 51/10 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01);
Abstract
Provided are novel dipeptide repeat (DPR) specific antibodies (e.g., human-derived antibodies) as well as synthetic variants and biotechnological derivatives thereof, capable of binding C9orf72 poly-glycine-alanine DPRs, as well as methods and uses related thereto. The antibody of the present invention can be used in pharmaceutical and diagnostic compositions for DPR protein-targeted immunotherapy and diagnostics.